InvestorsHub Logo
Followers 22
Posts 7075
Boards Moderated 0
Alias Born 05/14/2011

Re: Parkmart post# 53951

Tuesday, 10/16/2018 8:17:06 PM

Tuesday, October 16, 2018 8:17:06 PM

Post# of 58854
Yeah Park, this excerpt from Bloomberg is a pretty good frame of reference too:

University of Louisville, Stony Brook University and iCell Gene Therapeutics Receives Food and Drug Administration Clearance for Investigational New Drug for Treatment of Relapsed and Refractory T-Cell Leukemia and Lymphoma
Aug 7 18
University of Louisville, Stony Brook University and iCell Gene Therapeutics have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. The approach is the first to use chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR). Together, Stony Brook University, the University of Louisville and iCell Gene Therapeutics expect the first in-human Phase I clinical trial to begin accruing patients before the end of 2018.....

No qualms from me. Getting nowhere fast everywhere else. Obviously the reason for our new wholly owned subsidiary.

I can also understand our market plunge on not a lot of depth here. Speculation!!! Definately. Getting bought out now by a major pharma just a little closer.

IMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APDN News